Protective Effects of Murine Monoclonal Antibodies in Experimental Septicemia: E. coli Antibodies Protect Against Different Serotypes of E. coli

Salles, M.F.; Mandine, Eliane; Zalisz, R.; Guenounou, Moncef; Smets, P.

doi:10.1093/infdis/159.4.641

Cited by 28 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, some studies have attempted to elaborate subunit vaccines from known virulence factors. Hemolysin, capsule, or fimbrial proteins were shown to protect against ExPEC strains causing UTI (35,37,46) or systemic infections (66) in experimental models. The fimbrial adhesin known as FimH, a critical determinant for cystitis, was the most promising against UTI and has begun clinical trials.…”

mentioning

confidence: 99%

Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic Escherichia coli

et al. 2007

View full text Add to dashboard Cite

Extraintestinal pathogenic Escherichia coli (ExPEC) strains cause a large spectrum of infections. The majority of ExPEC strains are closely related to the B2 or the D phylogenetic group. The aim of our study was to develop a protein-based vaccine against these ExPEC strains. To this end, we identified ExPEC-specific genomic regions, using a comparative genome analysis, between the nonpathogenic E. coli strain K-12 MG1655 and ExPEC strains C5 (meningitis isolate) and CFT073 (urinary tract infection isolate). The analysis of these genomic regions allowed the selection of 40 open reading frames, which are conserved among B2/D clinical isolates and encode proteins with putative outer membrane localization. These genes were cloned, and recombinant proteins were purified and assessed as vaccine candidates. After immunization of BALB/c mice, five proteins induced a significant protective immunity against a lethal challenge with a clinical E. coli strain of the B2 group. In passive immunization assays, antigen-specific antibodies afforded protection to naive mice against a lethal challenge. Three of these antigens were related to iron acquisition metabolism, an important virulence factor of the ExPEC, and two corresponded to new, uncharacterized proteins. Due to the large number of genetic differences that exists between commensal and pathogenic strains of E. coli, our results demonstrate that it is possible to identify targets that elicit protective immune responses specific to those strains. The five protective antigens could constitute the basis for a preventive subunit vaccine against diseases caused by ExPEC strains.

show abstract

mentioning

confidence: 99%

Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic Escherichia coli

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Nonetheless, even if successful, the use of this vaccine will probably not extend to the many other infections caused by extraintestinal E. coli, since protection afforded by this vaccine appears to be through inhibition of bladder-specific adherence mediated by type 1 fimbriae (18). In animal models, passive or active immunization against capsule, O-specific antigen, and iron-regulated outer membrane proteins has afforded protection against systemic infection (4,14,33), and immunization with capsule, O-antigen, and P and type 1 fimbriae is protective against UTI due to ExPEC strains expressing these virulence factors (15-18, 21, 22). However, a vaccine based on capsule and/or O-specific antigens is impractical because of their significant antigenic heterogeneity (there are 80 capsular and Ͼ100 O-antigen serotypes).…”

mentioning

confidence: 99%

TheSiderophore Receptor IroN of Extraintestinal Pathogenic Escherichia coli Is a Potential VaccineCandidate

Russo¹,

McFadden²,

Carlino-MacDonald³

et al. 2003

Infect Immun

View full text Add to dashboard Cite

It would be medically and economically desirable to prevent the millions of annual extraintestinal infections and the thousands of associated deaths due to Escherichia coli. Outer membrane proteins are potential vaccine candidates for the prevention of these infections. This study tested the hypotheses that the siderophore receptor IroN is antigenic and that an IroN-specific antibody response confers protection in vivo. Subcutaneous immunization with denatured IroN resulted in a significant IroN immunoglobulin G (IgG)-specific response in serum (P < 0.0001) but not a systemic or mucosal IroN-specific IgA response. In a mouse model of ascending urinary tract infection, subcutaneous immunization with denatured IroN conferred significant protection against renal (P ‫؍‬ 0.0135 and 0.0095 in two independent experiments), but not bladder, infection. These data, together with the previously demonstrated role of IroN in virulence, its expression in human biologic fluids, and its prevalence among extraintestinal pathogenic E. coli strains, support further studies on the role of IroN as a vaccine candidate.

show abstract

“…Animal models have demonstrated the protective effect of immunization with capsules, somatic antigens and outer membrane proteins [14] and fimbriae of type 1 and P against urinary infections caused by bacteria expressing these types of virulence factors [15][16][17][18][19]. However, a vaccine based solely on specific capsular or somatic antigens does not seem feasible, given the great antigenic heterogeneity (more than 80 capsular antigens and more than 150 antigenic variants in extraintestinal E. coli).…”

Section: Discussionmentioning

confidence: 99%

Prospective Observational Cohort Study of the Efficacy of Bacterial Immune Prophylaxis in the Prevention of Uncomplicated, Recurrent Urinary Tract Infections

et al. 2019

View full text Add to dashboard Cite

Objective: To investigate the long-term prophylactic effect of a vaccine on lower urinary tract infections (UTI) of bacterial and the impact of the intensity of the symptoms on the quality of life (QoL). Methods: Adult female could be enrolled in this study if they had acute UTI at the enrolment visit and bacterial microbiological count of ≥10³ CFU/mL of Escherichia coli. Results: A total of 21 patients were included. Fifteen days after the administration of a vaccine for 3 months, the number of infections dropped almost to zero. Significant differences were observed in the QoL score (p < 0.05). The safety profile was good. Conclusions: In patients diagnosed with recurrent UTI and treated for 3 months with the vaccine the number of UTI episodes fell very quickly (15 days), and patients remained free of episodes and improved their QoL significantly for 1 year. These results suggest that bacterial vaccines are a possible effective alternative in the prevention of recurrent UTI.

show abstract

Protective Effects of Murine Monoclonal Antibodies in Experimental Septicemia: E. coli Antibodies Protect Against Different Serotypes of E. coli

Cited by 28 publications

References 28 publications

Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic Escherichia coli

Identification of Candidates for a Subunit Vaccine against Extraintestinal Pathogenic Escherichia coli

TheSiderophore Receptor IroN of Extraintestinal Pathogenic Escherichia coli Is a Potential VaccineCandidate

Prospective Observational Cohort Study of the Efficacy of Bacterial Immune Prophylaxis in the Prevention of Uncomplicated, Recurrent Urinary Tract Infections

Contact Info

Product

Resources

About